Embed Size (px)
Citation preview
1
ADNI2 - Private Partner Scientific Board (PPSB)
Susan De Santi (Piramal Pharma, Inc.),
PPSB Chair
Current ADNI 2 PPSB Partners
Dorothy Jones-Davis
Scientific Project Manager, Neuroscience
Foundation for the NIH
(301) 594-9255
FNIH Coordination and Organization
ADNI Cores
MRICliff Jack
PETBill Jagust
Biochemical BiomarkerLes Shaw and John Trojanowski
BiostatisticsLaurel Beckett
ClinicalRon Petersen & Paul Aisen
GeneticsAndy Saykin
NeuropathologyJohn Morris
PublicationsRobert Green
Pat ColeAdam Schwarz
Holly SoaresJohannes Streffer
TBD
Veronika LogovinskyNandini Raghavan
Nadeem SarwarLeanne Munsie
Enchi LiuRobert Paul
Mark SchmidtGreg Klein
Lee Honigberg
RARCTom Montine
Enchi LiuHolly Soares
PPSB Core Liaisons
ADNI PIMike Weiner
PPSB
PPSB working groups
Biofluid Biomarkers WGJohan Luthman
Clinical Endpoints WGVeronika Logovinsky,
Nandini Raghavan
1. pAD/MCI Endpoints and Methods2. Novel Tests for pre-MCI3. List of Datasets4. Computerized Cognitive Batteries
PET Endpoints WGMark Schmidt
PPSB ChairSusan De Santi 2015
InformaticsArt Toga
A goal of ADNI is to develop and validate methods for clinical trials
• PPSB has formalized a DD process for the selection of measures to be included in ADNI 3 and provide recommendations to ADNI Core leaders (e.g. clinical, cognitive, imaging, biomarkers, biofluids, etc.)
• An increase in commercial and competitive measures and markers being considered for ADNI; adding and subtracting precompetitive measures
• Inclusion of measures into ADNI 3 will be based on a solid analysis using
objective criteria outline key criteria for consideration of measures assure transparency on how measures are identified, vetted and selected define clear, efficient timeline (e.g. < 4 months) avoid duplication of efforts achieve alignment for the final recommendation
• DD team assembled (no links to possible providers) for full vetted process
• Academics and industry scientists are working together
Due Diligence (DD) Process for ADNI 3
Questions?
